1. Home
  2. AURE vs IMMP Comparison

AURE vs IMMP Comparison

Compare AURE & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prestige Wealth Inc. Class A Ordinary Shares

AURE

Prestige Wealth Inc. Class A Ordinary Shares

SELL

Current Price

$1.04

Market Cap

36.1M

Sector

Finance

ML Signal

SELL

Logo Immutep Limited

IMMP

Immutep Limited

SELL

Current Price

$3.31

Market Cap

31.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AURE
IMMP
Founded
2018
1987
Country
Hong Kong
Australia
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.1M
31.5M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
AURE
IMMP
Price
$1.04
$3.31
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 114.0K
26.0K
Earning Date
01-05-2027
09-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.26
52 Week High
$3.53
$5.36

Technical Indicators

Market Signals
Indicator
AURE
IMMP
Relative Strength Index (RSI) 42.99 56.26
Support Level $0.87 $3.06
Resistance Level $1.13 $3.55
Average True Range (ATR) 0.12 0.34
MACD 0.01 -0.01
Stochastic Oscillator 27.85 62.79

Price Performance

Historical Comparison
AURE
IMMP

About AURE Prestige Wealth Inc. Class A Ordinary Shares

Aurelion Inc is a publicly traded company building a digital gold risk and technology infrastructure around XAUT, on-chain gold backed by physical LBMA bars. XAUT combines the stability of physical gold with the efficiency of blockchain, giving investors access to a tokenized gold reserve that could serve as a hedge against inflation, currency devaluation, and crypto volatility. In parallel with building a business around tokenized gold, Aurelion provides wealth and asset management services.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: